公开(公告)号：KR1020110012089A

公开(公告)日：2011-02-09

申请号：KR1020090069646

申请日：2009-07-29

Applicant: 한국화학연구원 ,  에스케이케미칼주식회사

Inventor： 공영대 ,  조희영 ,  이태호 ,  최길돈 ,  전문국 ,  박우규 ,  공재양 ,  황순희 ,  정대영 ,  이봉용 ,  엄기안 ,  김재선 ,  류근호 ,  류제호 ,  김신애 ,  한혜영 ,  손현주 ,  이현정 ,  김용혁 ,  박성훈

IPC: C07D311/58 ,  C07D311/04 ,  C07D311/02

Abstract: PURPOSE: A 2-(2-amido methyl)-2-methyl-2H-benzypyrane compound is provided to ensure selective suppression to 11 beta-HSD 1 enzyme and to prevent and treat clucocorticoid regulatory diseases. CONSTITUTION: A 2-(2-amido methyl)-2-methyl-2H-benzopyrane compound is denoted by chemical formula 1. The 2-(2-amido methyl)-2-methyl-2H-benzopyrane compound is 3-methoxy-N-methyl-N-[(2-methyl-8-nitro-2H-chromen-2-yl)methyl]benzamide or 3-chloro-N-[(2,6-dimethyl-2H-chromen-2-yl)methyl]-N-methylbenzamide. A pharmaceutical composition contains the 2-(2-amido methyl)-2-methyl-2H-benzopyrane compound and prevents and treats impaired glucose tolerance(IGT), type 1 and 2 diabetes, insulin resistance, dyslipidemia or hypertension.

Abstract translation: 目的：提供2-（2-氨基甲基）-2-甲基-2H-苯并吡喃化合物，以确保对11β-HSD 1酶的选择性抑制，并预防和治疗类皮质激素调节性疾病。 构成：2-（2-氨基甲基）-2-甲基-2H-苯并吡喃化合物由化学式1表示。2-（2-酰氨基甲基）-2-甲基-2H-苯并吡喃化合物是3-甲氧基 - N-甲基-N - [（2-甲基-8-硝基-2H-色烯-2-基）甲基]苯甲酰胺或3-氯-N - [（2,6-二甲基-2H-色烯-2-基） 甲基] -N-甲基苯甲酰胺。 药物组合物含有2-（2-酰氨基甲基）-2-甲基-2H-苯并吡喃化合物，并预防和治疗葡萄糖耐量异常（IGT），1型和2型糖尿病，胰岛素抵抗，血脂异常或高血压。

公开(公告)号：KR1020070095715A

公开(公告)日：2007-10-01

申请号：KR1020060026255

申请日：2006-03-22

Applicant: 한국화학연구원

Inventor： 조희영 ,  공재양 ,  이성진 ,  정대영 ,  박우규 ,  김호정 ,  최길돈

IPC: A61K8/97 ,  A61Q19/02

Abstract: An external skin composition for skin whitening comprising the extract of Cassia tora or emodin isolated therefrom is provided to inhibit maturation and differentiation of melanin cells by inhibiting activity of c-Kit participating in signal transfer related to promotion of melanin synthesis caused by ultraviolet rays. An external skin composition for skin whitening comprises the extract of Cassia tora which is prepared by extracting Cassia tora with water, C1-C4 alcohol, mixed solvents thereof or chloroform, or emodin extracted from the Cassia tora extract which is obtained by extracting Cassia tora with methanol, fractioning the methanol extract with hexane and chloroform sequentially to obtain a chloroform fraction, and subjecting the chloroform fraction to the column chromatography using mixed solvents containing chloroform and methanol in a volume ratio of 20:1 to 5:1, and is a pharmaceutical composition for preventing and treating hemochromatosis or a cosmetic composition for skin whitening.

Abstract translation: 提供皮肤美白的外用皮肤组合物，其包含从其中分离的决明子或大黄素的提取物，以通过抑制参与与由紫外线引起的促进黑色素合成相关的信号传递的c-Kit的活性来抑制黑色素细胞的成熟和分化。 用于皮肤美白的外用皮肤组合物包括通过用水，C1-C4醇，其混合溶剂或氯仿萃取决明子制备的桂皮提取物，或从通过将Cassia tora萃取得到的大黄素提取物中提取的大黄素， 甲醇，依次用己烷和氯仿分取甲醇提取物，得到氯仿馏分，并用氯仿和甲醇的体积比为20:1〜5:1的混合溶剂对氯仿馏分进行柱色谱分离，为药物 用于预防和治疗血色素沉着的组合物或用于皮肤美白的化妆品组合物。

公开(公告)号：KR100394083B1

公开(公告)日：2003-08-06

申请号：KR1020000073122

申请日：2000-12-04

Applicant: 한국과학기술연구원 ,  한국과학기술원 ,  한국화학연구원 ,  학교법인 성신학원

Inventor： 고훈영 ,  최경일 ,  조용서 ,  배애님 ,  공재양 ,  정대영 ,  정선호 ,  정지영 ,  이희윤

IPC: C07D413/14

CPC classification number: C07D413/04 ,  C07D261/08

Abstract: The present invention relates to 4,5-dihydroisoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 and D4 receptors represented by the following Formula (1), and its preparation method through reductive amination reaction in the presence of reducing agent,wherein R1, R2, X and n are the same as defined in the specification.

Abstract translation: 本发明涉及对下式（1）所示的多巴胺D3和D4受体具有选择性生物活性的4,5-二氢异恶唑烷基哌嗪衍生物及其在还原剂存在下通过还原胺化反应的制备方法，其中R1，R2， X和n与说明书中定义的相同。

公开(公告)号：KR1020000011489A

公开(公告)日：2000-02-25

申请号：KR1019990026907

申请日：1999-07-05

Applicant: 한국화학연구원

Inventor： 정명희 ,  박준규 ,  조귀웅 ,  오정숙 ,  유복심 ,  정대영

IPC: C07D239/06 ,  A61K31/505

Abstract: PURPOSE: Title derivatives are prepared which has a good therapeutic activity of dys-mnesia and senile athymia. CONSTITUTION: Title compounds (formula 1; R is -H, -CH3, -CH2CH3, -CH2(CH2)3CH3, -CH2CH=CH2, etc.) and their pharmaceutical salt are prepared. Thus, 1.24 g of hydroxylamine hydrochloride is dissolved in water, and controlled to pH 7 by NaHCO3 saturated aqueous solution. The solution is refluxed for 2 hours in a mixed solution of 5-acetylpyrimidine and 50 ml of benzene using Dean-Stark column. Obtained solution is concentrated under reduced pressure to give 1.28 g of 1-pyrimidin-5-yl-(E)-ethanone oxime(yield 78 %).

Abstract translation: 目的：制备具有良好的失眠症和老年性无精症治疗活性的标题衍生物。 构成：制备标题化合物（式1; R为-H，-CH 3，-CH 2 CH 3，-CH 2（CH 2）3 CH 3，-CH 2 CH = CH 2等）及其药物盐。 因此，将1.24g盐酸羟胺溶于水中，并通过NaHCO 3饱和水溶液控制至pH7。 使用Dean-Stark柱，将溶液在5-乙酰基嘧啶和50ml苯的混合溶液中回流2小时。 得到的溶液在减压下浓缩，得到1.28g 1-嘧啶-5-基 - （E） - 乙酮肟（产率78％）。

公开(公告)号：KR1019990083132A

公开(公告)日：1999-11-25

申请号：KR1019990012805

申请日：1999-04-12

Applicant: 한국화학연구원

Inventor： 정명희 ,  박준규 ,  조귀웅 ,  오정숙 ,  천혜경 ,  정대영

IPC: C07D239/06 ,  A61K31/505

Abstract: 본발명은노인성치매치료제로유효한다음화학식 1로표시되는 1,2,3,4-테트라하이드로피리미딘유도체와이의약제학적으로허용가능한염, 그리고이들의제조방법에관한것이다. 상기화학식 1에서 : R은 -H, -CH, -CHCH, -CH(CH)CH, -CHCH=CH, -CHC≡CH,,또는을나타낸다. 본발명에따른상기화학식 1로표시되는 1,2,3,4-테트라하이드로피리미딘유도체는무스카린수용체작용물질로서치매치료제에응용될수 있고, 상기유도체는테트라하이드로피리딘의등배전자로서이미임상적으로치매치료제에쓰였던아레콜린및 밀라멜린약제와동등한치료효과를갖는다.

公开(公告)号：KR1019990015745A

公开(公告)日：1999-03-05

申请号：KR1019970038036

申请日：1997-08-09

Applicant: 한국화학연구원

Inventor： 박태호 ,  하영환 ,  정대영

IPC: C07D487/04 ,  C07D207/00 ,  C07D215/58

Abstract: 하기 화학식 1의 화합물 및 그의 제약학적으로 허용되는 염이 제공된다.

식 중,
R
1 은 탄소 원자수 1 내지 4의 저급 알킬기, 할로겐으로 치환된 탄소 원자수 1 내지 4의 저급 알킬기 또는 할로겐으로 치환된 페닐기이고,
X는 N, CH 또는 CY이고,
Y는 할로겐 또는 탄소 원자수 1 내지 4의 저급 알콕시이거나, 또는
R
1 및 X는 함께 -COCH
2 CH(CH
3 )-를 형성하고,
R
5 는 H 또는 아미노기이고,
R
2 및 R
3 은 각각 H, 탄소 원자수 1 내지 4의 저급 알킬기, 또는 할로겐으로 치환된 저급 알킬기이고,
n은 0 또는 1이다.